Atebimetinib Demonstrates 17.3 Month Median Overall Survival in Study

Immuneering’s atebimetinib demonstrated a median overall survival of 17.3 months, compared to 8.5 months for patients receiving standard of care in a previous study. The company also reported that the drug showed a strong tolerability profile, which CEO Ben Zeskind stated is closely linked to survival rates.

The findings about atebimetinib were presented at a recent medical conference. The data highlights a notable difference in survival duration between patients treated with Immuneering’s drug and those who received standard care in an earlier study. Furthermore, Immuneering emphasized the importance of the drug’s tolerability, suggesting it plays a significant role in the observed survival benefits.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI